Surrozen Initiates Dosing in Phase 1 Clinical Trial of SZN-043 for Severe Alcoholic Hepatitis
June 13, 2022 08:00 ET
|
Surrozen, Inc.
SZN-043 is a novel hepatocyte-specific R-spondin mimetic bispecific fusion protein targeting ASGR1First part of two-part Phase 1 trial starts in healthy volunteers SOUTH SAN FRANCISCO, Calif., June...
Surrozen Presents Data on Lead Therapeutic Candidates at Digestive Disease Week (DDW)
May 24, 2022 08:00 ET
|
Surrozen, Inc.
SOUTH SAN FRANCISCO, Calif., May 24, 2022 (GLOBE NEWSWIRE) -- Surrozen, Inc. (Nasdaq: SRZN), a company pioneering targeted therapeutics that selectively activate the Wnt pathway for tissue repair...
Surrozen Initiates Dosing in Phase 1 Clinical Trial of SZN-1326 for Moderate to Severe Ulcerative Colitis
May 18, 2022 08:00 ET
|
Surrozen, Inc.
SZN-1326 is a Fzd5-targeted Wnt-mimetic (SWAP) bi-specific antibodyFirst part of three-part Phase 1/1b trial starts in healthy volunteers SOUTH SAN FRANCISCO, Calif., May 18, 2022 (GLOBE NEWSWIRE)...
Surrozen Publishes Article in Cellular and Molecular Gastroenterology and Hepatology Demonstrating that SZN-1326, a Selective Wnt Mimetic, Stimulated Robust Colon Epithelial Regeneration and Ameliorated Colitis in an Acute Model of Inflammatory Bowel Disease (IBD)
May 16, 2022 08:00 ET
|
Surrozen, Inc.
SOUTH SAN FRANCISCO, Calif., May 16, 2022 (GLOBE NEWSWIRE) -- Surrozen, Inc. (Nasdaq: SRZN), a company pioneering targeted therapeutics that selectively modulate the Wnt pathway for tissue repair...
Surrozen Reports First Quarter 2022 Financial Results
May 11, 2022 08:00 ET
|
Surrozen, Inc.
SOUTH SAN FRANCISCO, Calif., May 11, 2022 (GLOBE NEWSWIRE) -- Surrozen, Inc. (“Surrozen” or the “Company”) (Nasdaq: SRZN), a company pioneering targeted therapeutics that selectively activate the...
Surrozen to Present at the BofA Securities 2022 Healthcare Conference
May 05, 2022 08:00 ET
|
Surrozen, Inc.
SOUTH SAN FRANCISCO, Calif., May 05, 2022 (GLOBE NEWSWIRE) -- Surrozen, Inc. (“Surrozen” or the “Company”) (Nasdaq: SRZN), a company pioneering targeted therapeutics that selectively activate the...
Surrozen Presents Data Supporting Potential of SZN-413 for the Treatment of Diabetic Retinopathy at the Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting
May 02, 2022 08:00 ET
|
Surrozen, Inc.
SOUTH SAN FRANCISCO, Calif., May 02, 2022 (GLOBE NEWSWIRE) -- Surrozen, Inc. (Nasdaq: SRZN), a company pioneering targeted therapeutics that selectively activate the Wnt pathway for tissue repair...
Surrozen Reports Fourth Quarter and Full Year 2021 Financial Results
March 24, 2022 08:00 ET
|
Surrozen, Inc.
SOUTH SAN FRANCISCO, Calif., March 24, 2022 (GLOBE NEWSWIRE) -- Surrozen, Inc. (“Surrozen” or the “Company”) (Nasdaq: SRZN), a company pioneering targeted therapeutics that selectively activate the...
Surrozen Announces Key 2022 Milestones for Lead Programs and Acceleration of Research Pipeline
January 10, 2022 08:00 ET
|
Surrozen, Inc.
-Initiation of Phase 1 clinical trials of SZN-1326 and SZN-043 expected in third quarter 2022 -Acceleration of preclinical programs includes nomination of lead candidate SZN-413 for retinopathies and...
Surrozen to Present Virtually at the 40th Annual J.P. Morgan Healthcare Conference
January 05, 2022 08:00 ET
|
Surrozen, Inc.
SOUTH SAN FRANCISCO, Calif., Jan. 05, 2022 (GLOBE NEWSWIRE) -- Surrozen, Inc. (“Surrozen” or the “Company”) (Nasdaq: SRZN), a company pioneering targeted therapeutics that selectively activate the...